Targeting IKK in androgen-independent prostate cancer causes phenotypic senescence and genomic instability AUTHORS

[1]  G. Delouya,et al.  DNA Damage- But Not Enzalutamide-Induced Senescence in Prostate Cancer Promotes Senolytic Bcl-xL Inhibitor Sensitivity , 2020, Cells.

[2]  Zhibin Wang,et al.  The kinase inhibitor BX795 suppresses the inflammatory response via multiple kinases. , 2020, Biochemical pharmacology.

[3]  Peter F. Johnson,et al.  Regulation of senescence and the SASP by the transcription factor C/EBPβ , 2019, Experimental Gerontology.

[4]  A. Mes-Masson,et al.  Exploiting interconnected synthetic lethal interactions between PARP inhibition and cancer cell reversible senescence , 2019, Nature Communications.

[5]  Young Hwa Kim,et al.  Cellular senescence in cancer , 2019, BMB reports.

[6]  P. Nelson,et al.  Androgen receptor splice variant-7 expression emerges with castration resistance in prostate cancer , 2018, The Journal of clinical investigation.

[7]  Jonathan R. Hall,et al.  C/EBPβ deletion in oncogenic Ras skin tumors is a synthetic lethal event , 2018, Cell Death & Disease.

[8]  Etienne Rouleau,et al.  BRCA1 and BRCA2 5′ noncoding region variants identified in breast cancer patients alter promoter activity and protein binding , 2018, Human mutation.

[9]  L. Xi,et al.  C/EBPβ enhances platinum resistance of ovarian cancer cells by reprogramming H3K79 methylation , 2018, Nature Communications.

[10]  R. Golsteyn,et al.  G2/M-Phase Checkpoint Adaptation and Micronuclei Formation as Mechanisms That Contribute to Genomic Instability in Human Cells , 2017, International journal of molecular sciences.

[11]  M. White,et al.  TBK1 Provides Context-Selective Support of the Activated AKT/mTOR Pathway in Lung Cancer. , 2017, Cancer research.

[12]  Z. Cai,et al.  TBK1 Promote Bladder Cancer Cell Proliferation and Migration via Akt Signaling , 2017, Journal of Cancer.

[13]  Tzong-Ming Shieh,et al.  BX795, a TBK1 inhibitor, exhibits antitumor activity in human oral squamous cell carcinoma through apoptosis induction and mitotic phase arrest. , 2015, European journal of pharmacology.

[14]  Yuanfang Ma,et al.  Acquisition of resistance to trastuzumab in gastric cancer cells is associated with activation of IL-6/STAT3/Jagged-1/Notch positive feedback loop , 2014, Oncotarget.

[15]  Hua Yu,et al.  Revisiting STAT3 signalling in cancer: new and unexpected biological functions , 2014, Nature Reviews Cancer.

[16]  A. Aplin,et al.  Targeting TBK1 Inhibits Migration and Resistance to MEK Inhibitors in Mutant NRAS Melanoma , 2014, Molecular Cancer Research.

[17]  J. Moffat,et al.  shRNA kinome screen identifies TBK1 as a therapeutic target for HER2+ breast cancer. , 2014, Cancer research.

[18]  Yuan Cao,et al.  Elevated expression of TANK-binding kinase 1 enhances tamoxifen resistance in breast cancer , 2014, Proceedings of the National Academy of Sciences.

[19]  Z. Culig,et al.  Androgen receptor signaling in prostate cancer , 2014, Cancer and Metastasis Reviews.

[20]  M. Jordá,et al.  Androgen Deprivation-Induced Senescence Promotes Outgrowth of Androgen-Refractory Prostate Cancer Cells , 2013, PloS one.

[21]  J. Cheng,et al.  IKBKE Phosphorylation and Inhibition of FOXO3a: A Mechanism of IKBKE Oncogenic Function , 2013, PloS one.

[22]  Wei Huang,et al.  Androgen deprivation induces senescence characteristics in prostate cancer cells in vitro and in vivo , 2013, The Prostate.

[23]  E. Diamandis,et al.  Molecular alterations during progression of prostate cancer to androgen independence. , 2011, Clinical chemistry.

[24]  D. Tindall,et al.  Androgen receptor signaling in prostate cancer development and progression , 2011, Journal of carcinogenesis.

[25]  A. Kozubík,et al.  Androgen depletion induces senescence in prostate cancer cells through down-regulation of Skp2. , 2011, Neoplasia.

[26]  D. Hanahan,et al.  Hallmarks of Cancer: The Next Generation , 2011, Cell.

[27]  J. Campisi,et al.  Four faces of cellular senescence , 2011, The Journal of cell biology.

[28]  M. White,et al.  TBK1 directly engages Akt/PKB survival signaling to support oncogenic transformation. , 2011, Molecular cell.

[29]  J. Campisi,et al.  DNA-SCARS: distinct nuclear structures that sustain damage-induced senescence growth arrest and inflammatory cytokine secretion , 2011, Journal of Cell Science.

[30]  M. Schmitz,et al.  SUMOylation-dependent localization of IKKepsilon in PML nuclear bodies is essential for protection against DNA-damage-triggered cell death. , 2010, Molecular cell.

[31]  J. Campisi,et al.  The senescence-associated secretory phenotype: the dark side of tumor suppression. , 2010, Annual review of pathology.

[32]  B. Dörken,et al.  C/EBPbeta regulates transcription factors critical for proliferation and survival of multiple myeloma cells. , 2009, Blood.

[33]  P. Cohen,et al.  Use of the pharmacological inhibitor BX795 to study the regulation and physiological roles of TBK1 and IkappaB kinase epsilon: a distinct upstream kinase mediates Ser-172 phosphorylation and activation. , 2009, The Journal of biological chemistry.

[34]  W. Hahn,et al.  Phosphorylation of the tumor suppressor CYLD by the breast cancer oncogene IKKepsilon promotes cell transformation. , 2009, Molecular cell.

[35]  M. Blasco,et al.  Cellular Senescence in Cancer and Aging , 2007, Cell.

[36]  C. Sousa.  Faculty Opinions recommendation of RalB GTPase-mediated activation of the IkappaB family kinase TBK1 couples innate immune signaling to tumor cell survival. , 2006 .

[37]  L. Boxer,et al.  Regulation of Bcl-2 expression by C/EBP in t(14;18) lymphoma cells , 2003, Oncogene.

[38]  Guo-Ping Zhou,et al.  Triggering the Interferon Antiviral Response Through an IKK-Related Pathway , 2003, Science.

[39]  R. Derynck,et al.  Transforming growth factor-beta inhibits adipocyte differentiation by Smad3 interacting with CCAAT/enhancer-binding protein (C/EBP) and repressing C/EBP transactivation function. , 2003, The Journal of biological chemistry.

[40]  M. Oya,et al.  Increased activation of CCAAT/enhancer binding protein-beta correlates with the invasiveness of renal cell carcinoma. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[41]  G. Bartsch,et al.  Interleukin-6 regulates androgen receptor activity and prostate cancer cell growth , 2002, Molecular and Cellular Endocrinology.

[42]  J. Kutok,et al.  Expression of geminin as a marker of cell proliferation in normal tissues and malignancies. , 2002, The American journal of pathology.

[43]  W. Farrar,et al.  Interleukin 6 activates androgen receptor-mediated gene expression through a signal transducer and activator of transcription 3-dependent pathway in LNCaP prostate cancer cells. , 2000, Cancer research.

[44]  Valeria Poli,et al.  The Role of C/EBP Isoforms in the Control of Inflammatory and Native Immunity Functions* , 1998, The Journal of Biological Chemistry.

[45]  C Roskelley,et al.  A biomarker that identifies senescent human cells in culture and in aging skin in vivo. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[46]  L. Chung,et al.  Androgen-independent cancer progression and bone metastasis in the LNCaP model of human prostate cancer. , 1994, Cancer research.

[47]  L. Chin,et al.  Biomarker Accessible and Chemically Addressable Mechanistic Subtypes of BRAF Melanoma. , 2017, Cancer discovery.

[48]  Linda J. Kuo,et al.  Gamma-H2AX - a novel biomarker for DNA double-strand breaks. , 2008, In vivo.

[49]  J. Diallo,et al.  Regulation of IkappaB kinase epsilon expression by the androgen receptor and the nuclear factor-kappaB transcription factor in prostate cancer. , 2007, Molecular cancer research : MCR.

[50]  Julien Sage,et al.  C/EBPbeta cooperates with RB:E2F to implement Ras(V12)-induced cellular senescence. , 2005, The EMBO journal.

[51]  T. Maniatis,et al.  IKKepsilon and TBK1 are essential components of the IRF3 signaling pathway. , 2003, Nature immunology.